Asan Pharmaceutical entered a strategic investment and commercial partnership with (주)파미르테라퓨틱스 (Pamir Therapeutics), committing 20억원 as a strategic investor. Under the agreement, Pamir Therapeutics will handle research, development and supply of a Parkinson’s disease in‑vitro diagnostic kit while Asan holds the domestic exclusive distribution rights. Asan will be responsible for sales and marketing activities for the kit in the domestic market. The funding was described in the articles as a strategic investment (SI). The announcement was covered by multiple outlets including Biospectator, Biotimes, Hankyung, Herald Economy and Medical Today. No other financial terms or additional investors were disclosed in the referenced coverage.

Total raised

$2M

Funding rounds

1

Latest round

Equity

Latest activity

Sep 2023